Mesenchymal stem cells have been identified in the synovial fluid of several species. This study was conducted to characterize chondroprogenitor (CP) cells in equine synovial fluid (SF) and to determine the effect of fibroblast growth factor 2 (FGF-2) on SF-CP monolayer proliferation and subsequent chondrogenesis. We hypothesized that FGF-2 would stimulate SF-CP proliferation and postexpansion chondrogenesis. SF aspirates were collected from adult equine joints. Colony-forming unit (CFU) assays were performed during primary cultures. At first passage, SF-cells were seeded at low density, with or without FGF-2. Following monolayer expansion and serial immunophenotyping, cells were transferred to chondrogenic pellet cultures. Pellets were analyzed for chondrogenic mRNA expression and cartilage matrix secretion. There was a mean of 59.2 CFU/mL of SF. FGF-2 increased the number of population doublings during two monolayer passages and halved the population doubling times. FGF-2 did not alter the immunophenotype of SF-CPs during monolayer expansion, nor did FGF-2 compromise chondrogenesis. Hypertrophic phenotypic markers were not expressed in control or FGF-2 groups. FGF-2 did prevent the development of a “fibroblastic” cell layer around pellet periphery. FGF-2 significantly accelerates in vitro SF-CP expansion, the major hurdle to clinical application of this cell population, without detrimentally affecting subsequent chondrogenic capacity.
Background: Progenitor cells exist in most tissues and body fluids. Synovial fluid chondroprogenitor cells have been described in several species; however, the specific phenotypic characteristics of these cells have not been defined. This study addressed the impacts of joint location and donor age variation on synovial fluid chondroprogenitor numbers, and determined whether synovial fluid chondroprogenitors express hypertrophic characteristics or a non-endochondral phenotype in chondrogenic culture. Methods: Synovial fluid was aspirated from the joints of healthy adult horses, and cells in the aspirates were expanded through two monolayer passages. The number of colony-forming units (CFU) in each aspirate was assessed after 14 days. Population doublings (PD) and PD times were calculated during the subsequent two passages. Passage 3 cells were used to determine osteogenic and adipogenic capacities, or were transferred to pellet cultures in chondrogenic medium containing TGF-β1 or BMP-2. Bone marrowderived MSCs and primary articular chondrocytes were cultured under similar conditions to provide reference values for chondrogenesis. Chondrogenesis was assessed by measuring collagen type II protein and sulfated glycosaminoglycan secretion, expression of chondrogenic mRNAs, and induction of ALP activity. Results: CFU counts varied considerably, but the majority of aspirates contained <50 CFU/ml. PDs were consistently between 2.0 and 3.0 during both passages. PD times varied from 0.2-0.4 days. Proliferation was not significantly influenced by anatomical location or donor age. Equine synovial fluid progenitors expressed osteogenic, adipogenic and chondrogenic phenotypes under appropriate conditions. Under chondrogenic conditions, synovial fluid cells increased collagen and aggrecan mRNA expression to levels comparable to bone marrow MSCs, although collagen type II protein secretion was less than half that of articular chondrocytes. In contrast to bone marrow MSCs, synovial fluid chondroprogenitors did not express collagen type X or increase ALP activity in response to TGF-β1 or BMP-2. Consistent with these observations, Runx2 and Mef2C expression in synovial fluid chondroprogenitors was 20-40 fold lower than in bone marrow MSCs. Conclusions: Synovial fluid chondroprogenitors are capable of robust non-hypertrophic chondrogenesis, whether stimulated by TGF-β1 or by BMP-2. These results indicate that synovial fluid cells are phenotypically suitable for articular cartilage repair/regeneration, although strategies to accelerate cell proliferation and synthesize a functional cartilage matrix in vivo will be required for clinically feasible cellbased therapies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.